This is thought to be due to increased expression of the membrane leptin receptor (ObRl/Rb) in ER+ breast cancer cells and its co-localization with the ER-α, together with leptin effects on breast cancer stromal aromatase activity [87] (Figure 5 and Figure 6). This evidence concerns the gene CYP19A1 and breast cancer.